Puissance Capital Management’s Corvus Pharmaceuticals CRVS Stock Holding History

Puissance Capital Management’s Portfolio CRVS Stock Details CRVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	$152K	Hold	38,010	–	–	0.88%	5
2020 Q2	$103K	Hold	38,010	–	–	0.44%	4
2020 Q1	$80K	Hold	38,010	–	–	0.93%	4
2019 Q4	$207K	Hold	38,010	–	–	0.51%	4
2019 Q3	$114K	Sell	38,010 -246,859	-87%	-$1.04M	0.25%	7
2019 Q2	$1.06M	Hold	284,869	–	–	1.04%	6
2019 Q1	$1.15M	Hold	284,869	–	–	0.93%	6
2018 Q4	$1.04M	Buy	+284,869	New	+$1.94M	1.19%	6

Other funds holding CRVS

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Puissance Capital Management's CRVS Position: Q3 2020 in Review

Puissance Capital Management held its Corvus Pharmaceuticals (CRVS) position steady in Q3 2020 at 38,010 shares worth $152K. The position accounts for 0.88% of the portfolio, ranked #5.

Puissance Capital Management first reported a position in CRVS in Q4 2018 and has held it in 8 quarters since. The position peaked at $1.15M in Q1 2019. 38 funds tracked by Wall St. Rank hold CRVS as of Q3 2020.

Puissance Capital Management held 38,010 shares of Corvus Pharmaceuticals worth $152K as of Q3 2020.
Puissance Capital Management left its Corvus Pharmaceuticals share count unchanged in Q3 2020.
Corvus Pharmaceuticals made up 0.88% of Puissance Capital Management's portfolio in Q3 2020, its #5 holding.
Puissance Capital Management first reported a position in Corvus Pharmaceuticals in Q4 2018 and has held it in 8 quarters since.
Puissance Capital Management's Corvus Pharmaceuticals position peaked at $1.15M in Q1 2019.
38 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2020.

Based on Puissance Capital Management's 13F filing for Q3 2020, filed 12 Nov 2020.